Holen Sie sich die Stockscreener-App
4.99
8.27%
-0.45
Schlusskurs vom Vortag:
$5.44
Offen:
$5.43
24-Stunden-Volumen:
400.40K
Relative Volume:
0.33
Marktkapitalisierung:
$136.74M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-33.99M
KGV:
-4.4194
EPS:
-1.1291
Netto-Cashflow:
$-29.87M
1W Leistung:
+75.09%
1M Leistung:
+370.75%
6M Leistung:
+289.84%
1J Leistung:
+253.90%
1-Tages-Spanne:
$4.7801
$5.47
1-Wochen-Bereich:
$2.97
$6.9099
52-Wochen-Spanne:
$1.00
$6.9099
An 2 Therapeutics Inc Stock (ANTX) Company Profile
Firmenname
An 2 Therapeutics Inc
Sektor
Branche
Telefon
(650) 331-9090
Adresse
1300 EL CAMINO REAL, SUITE 100, MENLO PARK
Compare ANTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
4.99 | 149.07M | 0 | -33.99M | -29.87M | -1.1291 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.66 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.28 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
703.20 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.58 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.41 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-09 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2024-08-09 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-07-03 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-04-02 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2024-02-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-12 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-02-12 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-01-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
Alle ansehen
An 2 Therapeutics Inc Aktie (ANTX) Neueste Nachrichten
Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study - PR Newswire
Tenax Therapeutics Inc (TENX) Reports Q4 Earnings - AlphaStreet
Trevi Therapeutics Announces Completion of End-of-Phase 2 - GlobeNewswire
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia - BioSpace
Drug film BXCL501 eases opioid withdrawal in Columbia University study - Stock Titan
AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV) - Business Wire
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement - Business Wire
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM - Intellia Therapeutics
Seres Therapeutics, Inc. Announces Executive Changes, Effective March 2, 2026 - marketscreener.com
Heron Therapeutics Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView
CAD-1005 Phase 2 data spur FDA EOP2 talks for Cadrenal (NASDAQ: CVKD) - Stock Titan
Cadrenal Therapeutics Announces Phase 2 Results with - GlobeNewswire
VA-funded Phase 2 stenoparib trial begins for Allarity (NASDAQ: ALLR) - Stock Titan
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need - Yahoo Finance
Perspective Therapeutics, Inc. (CATX) Builds Momentum With Funding and Trial Progress - Insider Monkey
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board - Yahoo Finance
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 earnings call transcript - MSN
Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update - PR Newswire
Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide - Yahoo Finance
Gain Therapeutics, Inc Advances Parkinson's Treatment to Phase 2 - TradingView
Sangamo Therapeutics IncOn Feb 2, Prathyusha Duraibabu terminated as principal financial officerSEC filing - marketscreener.com
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment - GlobeNewswire
Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer - Business Wire
Cullinan Therapeutics, Inc. Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN - Intellia Therapeutics
FDA lets Intellia resume MAGNITUDE-2 Phase 3 trial for ATTRv-PN - Stock Titan
Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium - Yahoo Finance
Actuate Therapeutics, Inc. Announces Initiation of Phase 1/2 Clinical Trial for Elraglusib Tablet in Advanced Cancers - Quiver Quantitative
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates - Yahoo Finance
GSK enters agreement to acquire RAPT Therapeutics - GSK
Peering Into Aquestive Therapeutics Inc's Recent Short Interest - Benzinga
Viking Therapeutics Unveils Promising Phase 2 Clinical Success, Fuels Stock Surge - timothysykes.com
Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2 - BioSpace
Actuate Therapeutics IncReports Positive Phase 2 Trial Data For ElraglusibSEC Filing - TradingView
Actuate Therapeutics, Inc. Reports Positive Phase 2 Trial Results for Elraglusib - TradingView — Track All Markets
Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity - Finviz
Sustained Therapeutics Reports Positive Phase 2 Results for Its Long-Acting Non-Opioid Medication for Chronic Pain - Yahoo Finance
Candid Therapeutics Plans to Initiate Multiple Phase 2 Studies Following Promising Clinical Data of T-cell Engagers in Autoimmune Diseases - Business Wire
Akebia Therapeutics Announces First Patient Dosed in Phase - GlobeNewswire
Cognition Therapeutics Publishes Phase 2 Clinical Results - GlobeNewswire
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression - GlobeNewswire
Marker Therapeutics Reports Positive Phase 1/2 Clinical Study Results for Multi-Antigen Targeted T Cells in Pancreatic Cancer Patients - Quiver Quantitative
Black Diamond Therapeutics' Silevertinib Shows 60% Response Rate in Preliminary Phase 2 Lung Cancer Data - Finviz
Beam Therapeutics Inc. (BEAM) reports updated data from BEACON Phase 1/2 Trial of Ristoglogene - MSN
Black Diamond Therapeutics’ Silevertinib Shows 60% Response Rate in Preliminary Phase 2 Lung Cancer Data - Yahoo Finance
Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene - Finviz
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy - PR Newswire
Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst (NASDAQ:PVLA) - Seeking Alpha
Aldeyra Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin - Insider Monkey
Will Viridian Therapeutics Inc. stock outperform international peersJuly 2025 Update & Stepwise Trade Signal Implementation - Улправда
Finanzdaten der An 2 Therapeutics Inc-Aktie (ANTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):